Every material Form 8-K Larimar Therapeutics, Inc. has filed with the SEC since June 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Larimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026, under an employment agreement with a $560,000 base salary and a 40% target annual bonus. He previously served as Chief Commercial Officer at Esperion Therapeutics from November 2025 to September 2026, and the filing describes a new senior operating role for the company.
Appointment effective September 29, 2026, as President and Chief Operating Officer
Base salary of $560,000 per year, a $35,000 cash signing bonus, and a target annual bonus of 40% of base salary
Inducement grants include an option on 800,000 shares and restricted stock units covering 50,000 shares, vesting over multiple years
Severance of nine months of base salary and COBRA coverage, or twelve months of salary plus target bonus and COBRA if terminated within one year after a change in control
Larimar Therapeutics reported a second quarter 2026 net loss of $32.8 million, or $0.30 per share, compared with $26.2 million, or $0.41 per share, a year earlier. Operating expenses rose on higher research and development and commercial preparation costs, and the company said it had $156.3 million in cash and marketable securities as of June 30, 2026, with a projected runway into the third quarter of 2027. Shareholders also received an update on the rolling BLA for nomlabofusp, which has its first module submitted, with completion expected in the second half of 2026.
Q2 2026 net loss of $32.8 million ($0.30 per share) vs. $26.2 million ($0.41 per share) in Q2 2025
Q2 2026 research and development expenses of $28.0 million vs. $23.4 million; general and administrative expenses of $6.4 million vs. $4.4 million
Cash, cash equivalents and marketable securities of $156.3 million as of June 30, 2026, with runway projected into Q3 2027
Open label study reported 10 participants with anaphylaxis who discontinued the study; first patient dosing in the global confirmatory Phase 3 study expected Q3 2026
Larimar Therapeutics said it has submitted the first module of a rolling Biologics License Application to the FDA for accelerated approval of nomlabofusp, after FDA meeting minutes said the existing data package appears sufficient for submission. The company also reported longer-term open label data, which showed improvements in some clinical measures alongside anaphylaxis in 10 of 43 patients, a safety finding shareholders should weigh.
First module of the rolling BLA submitted; remaining modules expected in the second half of 2026.
FDA meeting minutes say the existing data package appears sufficient for a BLA seeking accelerated approval; approval will be a matter of review.
Anaphylaxis occurred in 10 of 43 patients in the open label study, 9 of whom had prior exposure to nomlabofusp.
At 1 year, 100% (9/9) of participants had skin FXN levels above 50% of healthy volunteer mean; first patient dosing in a global Phase 3 study is expected in Q3 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Larimar Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →